Aug 7, 2024 · Suggested approach: Meropenem, imipenem-cilastatin, or ertapenem are preferred for the treatment of infections outside of the urinary tract caused by ESBL-E. For patients who are critically …

Recommendation: Extended-infusion meropenem is the preferred treatment for infections outside of the urinary tract caused by CRE resistant to ertapenem but susceptible to meropenem, when …

In recent years, ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, and cefepime-enmetazobactam have all been approved for use in …

Acceptable broad-spectrum antimicrobial regimens for pediatric patients with complicated intra-abdominal infection include an aminoglycoside-based regimen, a carbapenem (im-ipenem, …

For infections caused by P. aeruginosa isolates not susceptible to any carbapenem agent but susceptible to traditional β-lactams (e.g., cefepime), administration of a traditional agent as high-dose …

Jul 15, 2014 · Hospitalization and empiric antibacterial therapy with vancomycin plus antipseudomonal antibiotics such as cefepime, a carbapenem (imipenem-cilastatin or meropenem or doripenem) or …

Jul 17, 2025 · To optimize the selection of empiric antibiotic therapy for patients with suspected complicated UTI, we propose the following four-step approach: 1) assess the severity of illness (for …

Mar 30, 2022 · uggested for the treatment of infections caused by organisms at moderate to high risk of significant AmpC production (i.e., E. cloacae, K. aerogenes, and C when the cefepime MIC is ≤2 …

Aug 16, 2024 · In the ever-evolving landscape of antimicrobial resistance, health care providers and infectious diseases specialists are frequently confronted with formidable challenges in treating …

Aug 23, 2023 · Abstract Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are …